PSMA7 and Schnyder corneal dystrophy: In summary, the use of PGE2/poloxamer synperonic F108 as transduction enhancers provides a promising strategy to overcome current limitations in gene therapy for SCD and may further support the clinical translation of novel LV-based HSPC gene therapies for genetic blood cell disorders of different origins.